Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective

Journal of Psychopharmacology
Rainer ThomasiusA Schmoldt

Abstract

Although 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a known serotonergic neurotoxin in different animal species, there is to date no conclusive evidence of its neurotoxicity in humans. MDMA use was associated with impairments of psychological well-being, verbal memory and altered serotonergic functioning in a number of cross-sectional studies. Due to inherent methodological limitations, such as the notorious polydrug use of ecstasy users and lack of control of possible pre-existing differences between ecstasy users and control participants, researchers have called for well-controlled, prospective longitudinal studies to shed more light on the issue of MDMA neurotoxicity to the human brain. This longitudinal study investigated whether mood, cognition and central serotonin transporters (SERT) would deteriorate with continued MDMA use and whether or not they would recover over increasing periods of MDMA abstinence. In a repeated-measures design, 11 current and ten ex-ecstasy users, and 11 polydrug (but not MDMA) and 15 drug-naive controls participated three times within approximately two years. Both ecstasy user groups reported a polydrug use pattern besides heavy ecstasy use. Subjective reports of ecstasy use or abstine...Continue Reading

References

Sep 1, 1992·Journal of Computer Assisted Tomography·K WienhardW D Heiss
Dec 10, 1985·European Journal of Pharmacology·D R GehlertW Lovenberg
Feb 13, 1999·International Clinical Psychopharmacology·G GerraR Delsignore
Jan 6, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D M SempleE C Johnstone
Mar 4, 2000·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·A BuckC Burger
May 2, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F TuchtenhagenE Gouzoulis-Mayfrank
May 24, 2000·Drug and Alcohol Dependence·A C ParrottJ J Turner
Nov 1, 2001·Archives of General Psychiatry·H G PopeD Yurgelun-Todd
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Stephen J Kish
Oct 31, 2002·Human Psychopharmacology·Joerg DaumannEuphrosyne Gouzoulis-Mayfrank
Nov 13, 2002·Neurology·K I BollaJ L Cadet
May 27, 2003·Human Psychopharmacology·Marinus N Verbaten
Jul 19, 2003·Pharmacological Reviews·A Richard GreenM Isabel Colado
Sep 5, 2003·Psychopharmacology·Richard Ian DaftersAnnie Claire Talbot
Nov 18, 2003·Addiction·Louisa DegenhardtMichael Lynskey
Feb 26, 2004·Psychological Medicine·Karen L Hanson, Monica Luciana
Apr 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Maartje M L de WinGerard J den Heeten
Apr 17, 2004·Psychopharmacology·K McCardleC Stough
Jun 1, 2004·The Clinical Neuropsychologist·Carla Back-MadrugaRussell E Poland
May 17, 2005·Drug and Alcohol Dependence·Euphrosyne Gouzoulis-MayfrankJoerg Daumann
Sep 1, 2005·Addiction·R ThomasiusA Schmoldt

❮ Previous
Next ❯

Citations

Dec 4, 2003·Psychopharmacology·Jonathan P Roiser, Barbara J Sahakian
Sep 16, 2005·Psychopharmacology·Jonathan P RoiserBarbara J Sahakian
Oct 25, 2006·Psychopharmacology·Casey R Guillot, Mitchell E Berman
Jul 9, 2009·Psychopharmacology·Robin L Carhart-HarrisSue J Wilson
Mar 2, 2011·Psychopharmacology·Kevin S Murnane, Leonard L Howell
Feb 17, 2010·Neuropsychology Review·Claire E NulsenGeoffrey R Hammond
Apr 18, 2009·Molecular Neurobiology·João Paulo CapelaFélix Carvalho
Jun 5, 2007·Lancet·Philip N Murphy
Dec 19, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Johannes G RamaekersElia Formisano
Feb 23, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nina Bl UrbanMarc Laruelle
Apr 20, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew L BanksMichael A Nader
Nov 6, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Una D McCannGeorge A Ricaurte
Oct 22, 2013·Psychopharmacology·Simon N YoungChawki Benkelfat
Nov 4, 2006·Psychopharmacology·Ari D KalechsteinThomas F Newton
Apr 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Sudhakar SelvarajPaul Grasby
Nov 12, 2013·Expert Opinion on Drug Discovery·Adam Michael Stewart, Allan V Kalueff
Oct 7, 2009·Addiction·Neeltje VogelsRaymond J M Niesink
Mar 17, 2010·Behavioural Brain Research·Ruth TellezAlfredo Meneses
May 8, 2014·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Gregor GryglewskiPaul Cumming
Oct 1, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Sarah DurkinAndrew Harkin
Jul 24, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Andrea SarosiGabor Faludi
Nov 11, 2008·Annals of the New York Academy of Sciences·Leonard L Howell, Kevin S Murnane
Dec 25, 2010·Addiction·John E FiskFlorentia Hadjiefthyvoulou
Jan 22, 2014·Human Psychopharmacology·John E FiskCatharine Montgomery
Feb 1, 2011·Neuropharmacology·Alfredo MenesesCarlos Castillo
Mar 12, 2015·Pharmacology, Biochemistry, and Behavior·Susan Schenk, Sarah Bradbury

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.